Asylia News

Houston: the true third coast of innovation. Texas is home to more than 5,400 life science R&D and manufacturing firms, with more than 106,000 workers employed in related fields (THBI). As one of the top global biotechnology hubs, and home to the largest medical center in the world (Texas Medical Center), it’s no wonder JLABS …

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System Read More »

Asylia Therapeutics (“Asylia”), a new, privately-held, development stage biopharmaceutical company, headquartered in Houston at the Texas Medical Center, has finalized an exclusive worldwide license agreement with The University of Texas MD Anderson Cancer Center to develop first-in-class immune modulating therapies for cancer, autoimmune and infectious diseases, which collectively impact tens of millions of Americans annually. …

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement Read More »

Houston, Texas. June 6, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases has officially landed at Johnson & Johnson Innovation – JLABS in the Texas Medical Center (JLABS @ TMC). With over 34,000 square feet of common, wet lab, and office …

Asylia Therapeutics Moves into JLABS @TMC Read More »

Houston, Texas.  May 11, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases, today announced it has received a $3 million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT). Asylia will use the funding …

CPRIT Awards $3 Million to Asylia Therapeutics Read More »

The attached article demonstrates a key role for tumor-derived HSP70 in the development of robust anti-tumor immune responses. The results validate HSP70 as a target for the development of a novel class of immunomodulatory drugs, which is the focus of the Asylia platform. LEAR MORE Published by Oncogene: March 14 2014